Iodine-Refractory Thyroid Carcinoma

Author(s): Apar K. Ganti, Ezra E.W. Cohen.

Journal Name: Reviews on Recent Clinical Trials

Volume 1 , Issue 2 , 2006

Become EABM
Become Reviewer

Abstract:

The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodinerefractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.

Keywords: thyroid stimulating hormone, RET/PTC oncogene, TP53 Tumor Suppressor Gene, Chemotherapy, vascular endothelial growth factor (VEGF)

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 1
ISSUE: 2
Year: 2006
Page: [133 - 141]
Pages: 9
DOI: 10.2174/157488706776876526
Price: $58

Article Metrics

PDF: 3